Clinical Trial Update: SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SYD985 to physician's choice in HER2-positive metastatic breast cancer has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• SYD985 (trastuzumab duocarmazine)

Snippet

Sponsor: Byondis B.V. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2023-10-19